Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Predictive Factors and Magnitude of Response to Omalizumab and Mepolizumab in Allergic and Eosinophilic Severe Asthma: a Pragmatic Multicenter Trial in Belgium

Next Previous
Search
Trial Profile

Predictive Factors and Magnitude of Response to Omalizumab and Mepolizumab in Allergic and Eosinophilic Severe Asthma: a Pragmatic Multicenter Trial in Belgium

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mepolizumab (Primary) ; Omalizumab (Primary)
  • Indications Allergic asthma; Eosinophilia
  • Focus Therapeutic Use
  • Acronyms PREDICTUMAB

    • Most Recent Events

    • 26 Oct 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
    • 26 Oct 2022 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2023.
    • 02 Nov 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top